News
First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with pote ...
BioAge Labs (BIOA) announced that the first participant has been dosed in a Phase 1 clinical trial evaluating BGE-102, a structurally novel, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback